RE: Top up time16 Apr 2020 10:32
Just had a quick flick through the patent. It clearly covers SNGs use of INF B applied through inhaled form to the lower respiratory tract (most previous treatments to upper), for inluenza type illnesses which would need to cover two from following : cough, myalgia, headaches, sore throat, fever >37.8c. This therefore clearly protects SNGs product regarding COVID19 from competitors.